MedPath

Fluticasone propionate

Generic Name
Fluticasone propionate
Brand Names
Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
Drug Type
Small Molecule
Chemical Formula
C25H31F3O5S
CAS Number
80474-14-2
Unique Ingredient Identifier
O2GMZ0LF5W
Background

Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.

Indication

Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.

Associated Conditions
Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
Clinical Trials
Related News

FTC Issues New Warnings to Teva and Novartis Over Improper Orange Book Patent Listings

• The Federal Trade Commission has renewed challenges against Novartis, Teva, and other pharmaceutical companies for allegedly improper patent listings in the FDA's Orange Book. • The disputed listings involve more than 200 patents across 17 brand-name products, primarily for asthma, diabetes, epinephrine autoinjectors, and COPD medications. • According to the FTC, these improper device patent listings may delay generic competition, artificially inflate drug prices, and restrict patient access to affordable medications.

Breakthrough Therapies Set to Transform Eosinophilic Esophagitis Treatment Landscape

• The eosinophilic esophagitis (EoE) market is projected to grow from $1.8 billion in 2023 to a significantly higher value by 2034, driven by increased disease awareness and healthcare spending. • Three promising therapies—APT-1011 (Ellodi Pharmaceuticals), tezepelumab (AstraZeneca), and ESO-101 (EsoCap)—are advancing through clinical trials with specialized delivery mechanisms targeting the esophagus. • Despite recent approvals of DUPIXENT and JORVEZA, the EoE treatment landscape remains limited, with concerns about safety profiles and standardized dosing guidelines hindering widespread clinical adoption.

Pharmaceutical Industry Braces for $236 Billion Patent Cliff by 2030: Strategic Responses from Major Players

• The global pharmaceutical industry faces a $236 billion patent cliff between 2025-2030, with nearly 70 blockbuster drugs losing exclusivity and exposing major companies to significant revenue losses. • Key drugs approaching patent expiration include Merck's Keytruda ($25B), Bristol-Myers Squibb's Eliquis ($12B), and Johnson & Johnson's Stelara ($10.9B), forcing companies to rapidly adapt through pipeline diversification and cost-cutting measures. • Companies are responding with increased M&A activity, AI-driven R&D efficiency, and strategic pivots to high-growth therapeutic areas, while the cliff will likely improve drug affordability but potentially slow innovation.

GSK's Relvar Ellipta Demonstrates Superior Asthma Control in Landmark Real-World Study

• The Salford Lung Study shows patients using Relvar Ellipta had double the odds of achieving improved asthma control compared to standard care treatments. • The groundbreaking 52-week open-label trial involved 4,233 patients and was designed to reflect real-world clinical practice with minimal exclusion criteria. • Despite promising control outcomes, Relvar Ellipta carries boxed warnings for asthma-related death risk in children and adolescents, limiting its use in these populations.

Verona Pharma's Ensifentrine Shows Promise in COPD and COVID-19 Trials

• Verona Pharma's ensifentrine significantly reduced COPD exacerbations by 42% in the ENHANCE-2 phase 3 trial, paving the way for regulatory filings. • A pilot study is underway to evaluate ensifentrine's efficacy in hospitalized COVID-19 patients, leveraging its bronchodilator and anti-inflammatory properties. • Ensifentrine, a dual PDE3/PDE4 inhibitor, has received FDA support for phase 3 development in COPD, with two ENHANCE trials planned. • The ENHANCE trials will assess ensifentrine's impact on lung function and COPD symptoms, potentially addressing unmet needs in patients uncontrolled by current therapies.

Sarepta Seeks Accelerated Approval for DMD Gene Therapy SRP-9001

• Sarepta Therapeutics has submitted SRP-9001 (delandistrogene moxeparvovec) to the FDA for accelerated approval to treat ambulatory Duchenne muscular dystrophy (DMD) patients. • The filing is based on positive data from early-stage studies, showing improvements in clinical function and a consistent safety profile, while awaiting Phase 3 EMBARK results. • SRP-9001, a one-time gene therapy, delivers a shortened dystrophin gene via an AAV vector, addressing the underlying genetic defect in DMD patients. • If approved, SRP-9001 would offer a one-time treatment option for DMD, contrasting with Sarepta's existing chronic exon-skipping therapies.

FDA Approves DUPIXENT for Pediatric Eosinophilic Esophagitis, Expanding Treatment Options

The FDA has granted approval for DUPIXENT (dupilumab) to treat eosinophilic esophagitis (EoE) in children aged 1-11 years weighing at least 15 kg. The approval follows successful Phase III EoE KIDS trial results showing superior histological remission rates compared to placebo. This development represents a significant advancement in treating pediatric EoE, a condition affecting approximately 1 in 2,000 people.

Circassia Receives FDA Boost for COPD Drugs in the US

UK biotech firm Circassia has received favorable decisions from the FDA for its COPD drugs, Tudorza and Duaklir, marking a significant step in its business recovery. The company faces financial obligations to AstraZeneca due to licensing agreements, amidst a competitive market landscape.

FDA Moves to Remove Oral Phenylephrine as Decongestant Due to Ineffectiveness

• The FDA is moving to phase out oral phenylephrine, a common decongestant in over-the-counter cold medicines, after determining it is no more effective than a placebo. • This decision follows expert reviews of studies dating back to the 1960s, which revealed flaws and questionable data regarding phenylephrine's efficacy in oral form. • Consumers may need to switch to alternatives like pseudoephedrine (available behind the counter) or nasal sprays for congestion relief. • The FDA's decision is expected to take several months to finalize, allowing time for public comment and for drug manufacturers to reformulate or remove affected products.

Abingworth Reportedly Launching $1.5 Billion Clinical Trials Fund

• Abingworth, backed by Carlyle, is reportedly developing a $1.5 billion fund focused on late-stage clinical trials. • The fund aims to finance up to eight clinical studies, potentially through partnerships with major pharmaceutical companies. • Investments would be structured to secure a share of royalties from successful products, aligning with Abingworth's recent strategies.

Eupraxia's DiffuSphere Technology Shows Targeted Drug Release in Phase 2a EoE Program

• Eupraxia Pharmaceuticals' DiffuSphere technology demonstrates targeted drug release in a Phase 2a trial for Eosinophilic Esophagitis (EoE). • The data highlights DiffuSphere's ability to provide precise, localized drug delivery, potentially enhancing safety and efficacy. • The technology aims to minimize systemic exposure while maintaining effective drug concentrations at the target site for over six months. • These findings support DiffuSphere's potential as a platform for long-lasting drug delivery in various therapeutic areas.

Dupixent Approval by FDA: A New Era in COPD Treatment for Smokers

• The FDA has approved Dupixent (dupilumab) for COPD, marking the first targeted therapy for this progressive lung condition, particularly benefiting smokers. • Clinical trials demonstrated that Dupixent reduces moderate-to-severe COPD exacerbations by 30% and improves lung function significantly. • Dupixent targets type 2 inflammation pathways (IL-4 and IL-13), offering a novel approach for COPD patients with elevated eosinophils. • Several mid-stage drugs are in development, promising more options to transform COPD management, enhancing the treatment landscape.

Dupixent Approved for COPD: A New Era in Targeted Therapy

• The FDA has approved Dupixent (dupilumab) for COPD, marking the first targeted therapy addressing the IL-4 and IL-13 pathways linked to type 2 inflammation. • Clinical trials demonstrated Dupixent reduced moderate-to-severe COPD exacerbations by 30% over 52 weeks, with significant improvements in lung function. • COPD affects approximately 44 million people in the 7MM, with the market expected to reach USD 16 billion in 2023 and grow at a CAGR of 5% by 2034. • Emerging therapies like itepekimab, benralizumab, tezepelumab and mepolizumab are in development, poised to further transform the COPD treatment landscape.

FDA Proposes Ban on Oral Phenylephrine for Ineffective Nasal Decongestion Relief

• The FDA is proposing to ban oral phenylephrine, a common ingredient in OTC cold medications, due to evidence of its ineffectiveness as a nasal decongestant. • The proposal follows an FDA advisory committee's conclusion that oral phenylephrine does not work, with the public comment period open until May 7, 2025. • The ban applies only to oral forms of phenylephrine, not nasal sprays, and is based on effectiveness rather than safety concerns. • Experts recommend alternative treatments like nasal phenylephrine sprays, oral pseudoephedrine (behind the counter), nasal steroids, and antihistamine nasal sprays.

EP-104IAR Shows Promise for Knee Osteoarthritis Pain Relief in Phase 2 Trial

• Phase 2 trial data indicates EP-104IAR is safe and effective in reducing knee osteoarthritis (OA) pain for up to 14 weeks. • The SPRINGBOARD trial demonstrated a statistically significant improvement in WOMAC pain scores with EP-104IAR compared to the vehicle control group. • Treatment-emergent adverse events were similar between the EP-104IAR and control groups, with minimal effects on glucose and cortisol levels. • EP-104IAR's advanced formulation offers sustained pain relief and an improved safety profile, potentially advancing the standard of care for knee OA.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy